Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
age-related macular degeneration
Biotech
Roche drops $100M Kiniksa fibrosis drug from ph. 2 pipeline
Roche has waved goodbye to an inflammation drug from Kiniksa—as well as the $100 million the pharma paid for the therapy.
James Waldron
Jan 29, 2026 6:29am
Ocugen update charts course for rivalry with Apellis, Astellas
Jan 15, 2026 9:22am
Ollin eyes phase 3 after topping Vabysmo in early-stage trial
Jan 8, 2026 3:20pm
UK biotech eyes $1B deal to deliver eye gene therapy at doctor
Jan 6, 2026 6:25am
Aviceda eye disease hopeful fails to top Astellas med in phase 2
Dec 15, 2025 2:14pm
Otsuka pens $420M deal for Asia rights to 4DMT gene therapy
Oct 31, 2025 5:09am
